Particle in Medical Technology
Navigation Links
Particle in Medical Technology
Particle Sciences Expands Its Combination Product Capabilities
... BETHLEHEM, Pa., Aug. 19 /PRNewswire/ -- particle Sciences Inc. has expanded its Combination ... loaded polymeric devices. This addition gives particle Sciences the ability to go from bench scale to clinical trial material production. particle Sciences has recently completed Phase I of the ...... over other procedures for lipoprotein particle analysis because it both measures particle size accurately on the basis of ... particles present at each size independently of particle composition. We believe this approach ...
IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
... EKTA.ST), today announced a global particle therapy collaboration program to optimize the ... comprehensive cancer treatment solutions to the particle therapy market. Both companies have unique ... integration of both linear accelerator and particle therapy environments will have significant added ...NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
... Inc. (Nasdaq: NVAX ) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under ... diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, ...Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
... in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, ...... results for a new broadly immunogenic pandemic influenza virus-like particle (VLP) vaccine candidate that provided protection against several H5N1 ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, ...
... the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP-based, potent, ...
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
... results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer ... and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was ...... development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology. "Until now, it has been difficult to produce VLP ... of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, ...
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
... Wheeler C, Ferris DG, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 ... et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from ...... proprietary Tempo inhaler. MAP0005 uses the Company's proprietary particle technology to combine the corticosteroid and beta-agonist components into a single drug particle in a fixed, pre-specified ratio. MAP Pharmaceuticals believes this ...
... al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from ... HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types ...
Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
... studies of its recombinant trivalent seasonal influenza virus-like particle (VLP) vaccine. The trivalent seasonal influenza vaccine is the second of ... current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
... bioprocess solutions and design expertise and Novavax's virus- like particle (VLP) and manufacturing platform. Health planners around the world are ... current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
... development costs related to advancing the Company's two lead virus-like particle ("VLP")-based vaccine candidates against pandemic and seasonal influenza. ... current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
... results of pre-clinical immunological studies of improved HIV-1 virus-like particle (VLP) vaccines being developed by scientists at Novavax and leading ... current preventives options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing ...... or IsoCrom. PARI's Comparative in-vitro assessment of IsoCrom & a novel 6% DSCG formulation Sophisticated aerodynamic droplet and particle size assessments in a cascade impactor operated at different humidity levels revealed how delivery and deposition performance of aerosols can be ...
Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year
... of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton therapy at a number of hospitals beginning with the first installation at Barnes Jewish Hospital in St. Louis, ...... for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, ...
... for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, ...
New Proton Therapy Equipment Enables More Tumors to be Treated
... past four years by IBA in collaboration with Massachusetts General Hospital and the UF Proton Therapy Institute. IBA is the leading manufacturer of particle therapy equipment, with international headquarters in Belgium and a United States proton therapy headquarters in Jacksonville. "The immediate ...... liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 ...
... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...
Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional ...Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. ...... half of the radioactivity is lost every 20 minutes. This means that it must be manufactured onsite, a process that requires a cyclotron (a type of particle accelerator), which is rarely found in community hospitals. This limitation has prompted a search for longer-lived tracers, such as 18F-labeled ...
Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent recombinant vaccines utilizing a new, efficient manufacturing solution. Additional ...FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.
... ETDRS chart at 12 months. In contrast to previous forms of radiation therapy for wet AMD, NeoVista's therapy delivers a one-time peak dose of beta particle energy (24 Gy) directly to the lesion, and the normal retinal vasculature receives minimal exposure. Utilizing strontium 90, the focused energy is ...... stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based highly potent, recombinant vaccines utilizing a new, efficient manufacturing solution. ...
Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
... creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the Company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other ...PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial
... to PARI when developing new medications," said Lisa Cambridge, director of Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fine particle nebulizer that enables delivery of aerosols to the smaller airways of the lungs -- beneficial for successful respiratory therapies." Known as ...... creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral ...
Novavax CEO to Present at ACUMENBioFin's 9th Annual Healthcare Conference
... creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral ...... scale, The Eclipse family of PET cyclotrons is Siemens solution for radioisotope production. The Eclipse cyclotron is an 11 MeV, negative ion, single particle accelerator designed for clinical and commercial production and distribution of 18-fluoride-based radiotracers, as well as production N- 13, 0-15 and ...
Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol
... 5 in the journal Nature Structural & Molecular Biology in a paper entitled "The Refined Structure of Nascent HDL Reveals a Key Functional Domain for particle Maturation and Dysfunction." It builds upon the researchers' previous work which determined that not all HDL helps protect arteries from becoming ...... which does not bind CD20, and the standard beta particle emitting radioimmunoconjugate for CD20-positive ... that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and ... novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal ...
Other ContentstreatmenttreatmenttreatmenttreatmenttreatmenttreatmenttreatmenttreatmenttreatmenttreatmentempiricalempiricalempiricalempiricalisolatedisolatedisolatedisolatedisolatedisolatedisolatedisolatedisolatedscanscanscanscanscanscanscanextracorporealextracorporealliftliftliftliftliftliftOther TagsABCABCcelebratecelebrateNSANSANSAdoubledstressesportportportportportportportportlagsOther Tagscataracts 2treatment 2treatment 3treatment 4treatment 5treatment 6treatment 7treatment 8treatment 9treatment 10advances 2advances 3advances 4advances 5advances 6advances 7advances 8advances 9advances 10failure 2failure 3failure 4failure 5failure 6failure 7failure 8failure 9failure 10kidney 2kidney 3kidney 4kidney 5kidney 6kidney 7kidney 8kidney 9kidney 10degrades 2land 2land 3land 4land 5land 6land 7land 8land 9land 10assessment 2assessment 3assessment 4assessment 5
(Date:11/23/2009)...research presents strong evidence that the "synerg...or traffic-related pollution and indoor endotoxin ...he other exposure alone. , Environmental healt...College of Medicine have shown that children expos...s and indoor endotoxin during early life are six t...
(Date:11/23/2009)...by the Wildlife Conservation Society says that wes...he Republic of Congopart of the "mother lode" of m...becoming increasingly threatened by growing humans...protection of the swamp forests adjacent to the so...ecent surveys confirmed that high densities of the...
(Date:11/23/2009)... The only swine vaccine available for the H1N1 vir...d with the virus. The vaccination marks the first ...ed with the pandemic flu., Iowa State University...oped the vaccine this summer and has been shipping...as and Illinois for several weeks., The latest v...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Congressmen Mike Ross and Kendrick Meek Introduce Bill to Protect Medicare Patients Who Require Medical Oxygen Therapy at Home 51965 1Congressmen Mike Ross and Kendrick Meek Introduce Bill to Protect Medicare Patients Who Require Medical Oxygen Therapy at Home 51965 2Congressmen Mike Ross and Kendrick Meek Introduce Bill to Protect Medicare Patients Who Require Medical Oxygen Therapy at Home 51965 3GSK to Announce Q2 Results July 22 2009 51962 1GoHealthInsurance Announces Appointment of Mike Owens as Senior Vice President 51959 1GoHealthInsurance Announces Appointment of Mike Owens as Senior Vice President 51959 2(Date:11/27/2009)...lus low-emission vehicles may reduce future diseas...v. 27 (HealthDay News) -- Encouraging city dweller...offer much greater public health benefits than inc...hers have found. , The study compared the proje...and transport scenarios for London, England, and D...
(Date:11/27/2009)... , SEATTLE, Nov. 27 Allrecipe...d-high Thanksgiving traffic numbers, with more tha..., providing a clear picture of what was served on ...Thanksgiving meal in 2009 weighed in at 2,225 calo...ear,s feast. According to the Allrecipes site, Sw...
(Date:11/27/2009)... Multi-purpose bilingual coloring books design...the business community to educate - inform parents...Safety issues to Dinosuars to ABC,S and a host of ...is, MO (PRWEB) November 27, 2009 -- Today’s ...to keep them busy any hour of the day, but one of ...
(Date:11/27/2009)... Three new interactive anatomy education apps ...s expand health sciences learning opportunities fo... Durham, NC (Vocus) November 27, 2009 -- Modality...), a division of Wolters Kluwer Health, today anno...ion apps on the App Store. Clemente’s Anatom...
(Date:11/26/2009)...ON, N.J., Nov. 27 The diabetes pop...er the next 25 years and annual medical spending o... from $113 billion today, according to a study pub...The National Changing Diabetes ® Program (NC...nalysis by a team from the University of Chicago. ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4[0] More Foot Power, Less Car Pollution Best for Health[0] It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories[1] Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books [0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |